Business Wire·Oct 27, 2026
Electromed, Inc. to Report Q1 Fiscal 2027 Financial Results on November 10, 2026NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. to Report Q1 Fiscal 2027 Financial Results on November 10, 2026.
Electromed's airway-clearance device franchise has compounded revenue from $13.9M in 2024Q3 to $19.4M in 2026Q4 (+11.6% year over year), while gross margin widened nearly 400 basis points to 78.7% and operating income more than doubled to $3.8M on SG&A growth of 32% versus 39.6% revenue growth, indicating genuine…
Price trend, volume and key moving averages
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 25, 2026 | $0.39+23.1% vs $0.32 | $19M+0.4% vs $19M |
Q2 2026 May 12, 2026 | $0.35+34.6% vs $0.26 | $19M+5.5% vs $18M |
Q1 2026 Feb 10, 2026 | $0.32+18.5% vs $0.27 | $19M+4.7% vs $18M |
Q4 2025 Nov 12, 2025 | $0.25+13.6% vs $0.22 | $17M-7.7% vs $18M |
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. to Report Q1 Fiscal 2027 Financial Results on November 10, 2026.
Cytosorbents (NASDAQ: CTSO - Get Free Report) and Electromed (NYSE: ELMD - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership and dividends. Analyst Recommendations This is a breakdown of recent ratings
Squarepoint Ops LLC acquired a new position in Electromed, Inc. (NYSE: ELMD) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 19,498 shares of the company's stock, valued at approximately $825,000. Squarepoint Ops LLC owned approximately 0.23% of Electromed as of
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. to Participate in the H.C. Wainwright 28th Annual Global Investment Conference and LD Micro 20th Annual Main Event.
Benchmark ELMD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Electromed, Inc. (ELMD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $27.17 | $224.97M | 20.89 | 15.28% | 15.32% | 23.38% | — | |
| $6.03 | $163.26M | -4.50 | 3.86% | -10.46% | -20.06% | — | |
| $100.61 | $6.55B | 25.50 | 0.5% | 17.28% | 21.72% | — | |
| $2.56 | $108.13M | -2.60 | 8.01% | -47.93% | -98.23% | — | |
| $142.71 | $7.14B | 24.25 | 14.17% | 11.48% | 12.8% | — | |
| $109.93 | $191.48B | 40.64 | 5.67% | 9.75% | 9% | 2.14% |
Electromed, Inc. (ELMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Electromed, Inc. (ELMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 25, 2026·SEC
May 12, 2026·SEC
Feb 10, 2026·SEC
Get notified when ELMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Electromed, Inc. (ELMD) stock FAQ — growth, dividends, profitability & financials explained
Electromed, Inc. (ELMD) reported $73.8M in revenue in fiscal year 2026, which is also its trailing twelve months. That is 743% more than the $8.8M of fiscal year 2008.
Electromed, Inc. (ELMD) grew revenue by 15.3% over the trailing twelve months, compared with the twelve months before.
Yes. Electromed, Inc. (ELMD) earned $11.3M in net income over the trailing twelve months (a 15.3% net margin).
Electromed, Inc. (ELMD) had a return on equity (ROE) of 23.4% over the trailing twelve months. That is well above the market's typical 10-15%.
Electromed, Inc. (ELMD) generated $9.3M in free cash flow over the trailing twelve months.
